The Registry of Toxic Effects of Chemical Substances

Diethylamine, 2,2' - dichloro - N - methyl -

RTECS #: IA1750000

CAS #: 51-75-2

UPDATE: February 2008 MW: 156.07 MF: C5H11Cl2N


NOTE:

TABLE OF CONTENTS:
  1. SYNONYMS:
  2. SKIN AND EYE IRRITATION DATA:
  3. MUTATION DATA:
  4. REPRODUCTIVE EFFECTS DATA:
  5. TUMORIGENIC DATA:
  6. ACUTE TOXICITY DATA:
  7. REVIEWS:
  8. NIOSH DOCUMENTATION AND SURVEILLANCE:
  9. STATUS IN FEDERAL AGENCIES:
  10. REFERENCES:

SYNONYMS:

  1. 2,2' - Dichloro - N - methyldiethylamine
  2. 2,2' - Dichlorodiethyl - methylamine
  3. 2 - Chloro - N - (2 - chloroethyl) - N - methylethanamine
  4. Bis (2 - chloroethyl) methylamine
  5. Bis (beta - chloroethyl) methylamine
  6. Chlorethazine
  7. Chlormethine
  8. Di (2 - chloroethyl) methylamine
  9. ENT - 25294
  10. Ethanamine, 2 - chloro - N - (2 - chloroethyl) - N - methyl -
  11. HN2
  12. MBA
  13. MEC
  14. Mechlorethamine
  15. Mecloretamina (Italian)
  16. Methylbis (2 - chloroethyl) amine
  1. Methylbis (beta - chloroethyl) amine
  2. Methyldi (2 - chloroethyl) amine
  3. Mustargen
  4. Mustine
  5. Mutagen
  6. N,N - Di (chloroethyl) methylamine
  7. N - Methyl - 2,2' - dichlorodiethylamine
  8. N - Methyl - bis (2 - chloroethyl) amine
  9. N - Methyl - bis (beta - chloroethyl) amine
  10. N - Methyl - bis - chloraethylamin (German)
  11. N - Methyl - lost (German)
  12. NSC 762
  13. Nitrogen mustard
  14. T - 1024
  15. TL 146
  16. beta,beta' - Dichlorodiethyl - N - methylamine


SKIN AND EYE IRRITATION DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
eye
rabbit 		400 µg severe AJOPAA 29,1553,1946
eye
rabbit 		20 µg/30 minute severe INOPAO 15,308,1976
skin
human 		0.2%/1 hour moderate BJDEAZ 147,926,2002


MUTATION DATA AND REFERENCES:

SYSTEM TEST ROUTE/
ORGANISM/
TISSUE 		DOSE REFERENCE
cytogenetic analysis hamster ovary 100 µmol/L MUREAV 23,259,1974
cytogenetic analysis human leukocyte 10 µg/L CNREA8 33,1829,1973
cytogenetic analysis human HeLa cell 100 nmol/L TXCYAC 9,21,1978
cytogenetic analysis human lymphocyte 0.1 mmol/L/24 hour (-enzymatic activation step) MUREAV 542,117,2003
cytogenetic analysis subcutaneous
mouse 		680 µg/kg MUREAV 58,67,1978
cytogenetic analysis mouse Ascites tumor 40 nmol/L PHARAT 32,178,1977
cytogenetic analysis oral
rat 		1 mg/kg BJCAAI 6,173,1952
cytogenetic analysis intraperitoneal
rat 		4 mg/kg/24 hour LBANAX 3,157,1969
cytogenetic analysis intravenous
rat 		900 µg/kg CTKIAR 1,289,1968
dominant lethal test parenteral
mouse 		2,250 µg/kg MUREAV 140,193,1984
dominant lethal test intraperitoneal
mouse 		3 mg/kg CTRRDO 68,855,1984
dominant lethal test intravenous
mouse 		2 mg/kg MUREAV 191,171,1987
dominant lethal test unreported route
other insects 		2 pph/30 minute- continuous AESAAI 62,790,1969
dominant lethal test oral
other insects 		1,000 ppm AESAAI 62,790,1969
dominant lethal test parenteral
other insects 		1 µg MUREAV 7,63,1969
DNA adduct Escherichia coli 5 µmol/L MUREAV 89,95,1981
DNA adduct other microorganisms 3 gm/L BIJOAK 89,138,1963
DNA damage hamster kidney 500 nmol/L PNASA6 79,2942,1982
DNA damage human other cell types 1 µmol/L CNREA8 47,1361,1987
DNA damage human other cell types 4 µmol/L EJCAEL 27,1039,1991
DNA damage human lymphocyte 500 µg/L MUREAV 132,63,1984
DNA damage human other cell types 10 µmol/L/24 hour JAPTO* 20,S35,2000
DNA damage mammal (species unspecified) kidney 100 µmol/L JTEHD6 6,333,1980
DNA damage mouse embryo 170 nmol/L CBINA8 38,75,1981
DNA damage intraperitoneal
mouse 		2,500 µg/kg OFAJAE 51,1,1974
DNA damage unreported route
mouse 		2,400 µg/kg PACHAS 42,209,1975
DNA damage mouse fibroblast 25 µmol/L BEXBAN 92,1692,1981
DNA damage unreported route
mouse 		300 µg/kg PAACA3 24,246,1983
DNA damage other fish testis 7,100 mmol/L ABBIA4 97,80,1962
DNA damage other microorganisms 10 µmol/L/90 minute- continuous BBACAQ 174,674,1969
DNA damage rat liver 50 µmol/L CALEDQ 18,163,1983
DNA damage rat other cell types 1 µmol/L CNREA8 40,3186,1980
DNA damage rat other cell types 10 µmol/L/24 hour JAPTO* 20,S35,2000
DNA damage salmon sperm 100 mmol/L ABBIA4 97,80,1962
DNA inhibition hamster lung 2 µmol/L CRNGDP 4,269,1983
DNA inhibition human HeLa cell 2 mg/L JCLLAX 69,331,1967
DNA inhibition human lymphocyte 400 µg/L MUREAV 132,63,1984
DNA inhibition intravaginal
mouse 		100 ppm JIDEAE 62,378,1974
DNA inhibition mouse other cell types 100 µg/L CNREA8 37,2998,1977
DNA inhibition mouse leukocyte 10 µmol/L BCPCA6 18,1229,1969
DNA inhibition other microorganisms 2 mmol/L MGGEAE 150,301,1977
DNA inhibition parenteral
rat 		400 µg/kg/4 day- continuous JNCIAM 55,713,1975
DNA inhibition rat other cell types 400 nmol/L CBINA8 39,191,1982
DNA repair Bacillus subtilis 10 µg/plate TAKHAA 44,96,1985
DNA repair other microorganisms 386 µg/plate BIZNAT 95,463,1976
unscheduled DNA synthesis domestic animal kidney 1 µmol/L CBINA8 13,243,1976
unscheduled DNA synthesis Escherichia coli 300 µmol/L ZKKOBW 92,177,1978
unscheduled DNA synthesis hamster embryo 5 µmol/L JTEHD6 6,333,1980
unscheduled DNA synthesis human fibroblast 160 µg/L TXCYAC 21,151,1981
unscheduled DNA synthesis human leukocyte 100 µmol/L CALEDQ 18,305,1983
unscheduled DNA synthesis mammal (species unspecified) lymphocyte 1 µmol/L CBINA8 8,113,1974
unscheduled DNA synthesis mammal (species unspecified) kidney 10 µmol/L JTEHD6 6,333,1980
unscheduled DNA synthesis mouse testis 10 µmol/L ARTODN 37,195,1977
unscheduled DNA synthesis unreported route
mouse 		15,600 nmol/kg PAACA3 24,248,1983
unscheduled DNA synthesis rat liver 10 µmol/L JTEHD6 6,333,1980
unscheduled DNA synthesis intraperitoneal
rat 		3 mg/kg CANCAR 36,2364,1975
unscheduled DNA synthesis rat other cell types 20 µmol/L PSEBAA 157,688,1978
mutation in microorganisms Aspergillus nidulans 6,500 µmol/L (-enzymatic activation step) MUREAV 3,145,1966
mutation in microorganisms Escherichia coli 1 nmol/L (-enzymatic activation step) APTOA6 53,421,1983
mutation in microorganisms Escherichia coli 100 µg/L (+enzymatic activation step) RCOCB8 16,523,1977
mutation in microorganisms Euglena gracilis 400 mg/L (-enzymatic activation step) SCIEAS 148,497,1965
mutation in microorganisms Neurospora crassa 4 mmol/L/30 minute (-enzymatic activation step) PNASA6 35,581,1949
mutation in microorganisms other microorganisms 1,500 ppm (-enzymatic activation step) APMBAY 6,45,1958
mutation in microorganisms other microorganisms 10 mg/L (-enzymatic activation step) MOPMA3 6,667,1970
mutation in microorganisms other microorganisms 1 pph (-enzymatic activation step) FOMIAZ 17,248,1972
mutation in microorganisms Salmonella typhimurium 40 µg/plate (+enzymatic activation step) CNREA8 37,2209,1977
mutation in microorganisms Salmonella typhimurium 50 µg/plate (-enzymatic activation step) PNASA6 72,5135,1975
mutation in microorganisms Saccharomyes cerevisiae 200 mg/L/1 hour (-enzymatic activation step) GENTAE 78,1101,1974
micronucleus test intraperitoneal
mouse 		2,500 µg/kg TOXID9 1,40,1981
gene conversion and mitotic recombination oral
Drosophila melanogaster 		7.8 mmol/L/2 hour EMMUEG 36,195,2000
gene conversion and mitotic recombination oral
Drosophila melanogaster 		2.6 mmol/L/48 hour EMMUEG 36,195,2000
gene conversion and mitotic recombination Saccharomyes cerevisiae 14 mg/L MUREAV 204,239,1988
mutation in mammalian somatic cells mouse lymphocyte 40 nmol/L MUREAV 25,107,1974
morphological transform mouse embryo 100 nmol/L CBINA8 38,75,1981
morphological transform mouse fibroblast 0.1 µg/L/21 day (-enzymatic activation step) EMMUEG 37,231,2001
other mutation test systems Escherichia coli 1 nmol/tube MUREAV 147,79,1985
other mutation test systems human HeLa cell 20 mg/L BBACAQ 349,389,1974
other mutation test systems mouse leukocyte 10 µmol/L BCPCA6 18,1229,1969
other mutation test systems mouse other cell types 100 µg/L CNREA8 37,2998,1977
phage inhibition capacity Escherichia coli 500 µg/L APMBAY 12,234,1964
phage inhibition capacity other microorganisms 100 µmol/L COREAF 234,2238,1952
phage inhibition capacity other microorganisms 800 mg/L JGMIAN 8,116,1953
phage inhibition capacity other microorganisms 100 mg/L JGMIAN 8,116,1953
phage inhibition capacity Salmonella typhimurium 800 mg/L JGMIAN 8,116,1953
sister chromatid exchange hamster lung 100 µg/L CNREA8 44,3270,1984
sister chromatid exchange hamster ovary 1 µmol/L NATUAS 258,121,1975
sister chromatid exchange human other cell types 400 nmol/L CNREA8 47,1361,1987
sister chromatid exchange rat other cell types 500 nmol/L CNREA8 45,3460,1985
sex chromosome loss and nondisjunction inhalation
Drosophila melanogaster 		100 pph/7 minute PREBA3 62,284,1946/1947
sex chromosome loss and nondisjunction human lymphocyte 150 µg/L MUREAV 190,69,1987
specific locus test oral
Drosophila melanogaster 		2,000 ppm/2 hour MUREAV 120,233,1983
specific locus test intravenous
mouse 		2 mg/kg MUREAV 227,81,1989
specific locus test parenteral
other insects 		0.5 mmol/L/24 hour MUREAV 478,107,2001
specific locus test oral
other insects 		3 mmol/L/2.5 day MUREAV 478,107,2001
sperm morphology intraperitoneal
mouse 		7,500 µg/kg/5 day- intermittent CMMUAO 5,257,1978


REPRODUCTIVE EFFECTS DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraperitoneal
mouse 		lowest published toxic dose: 4 mg/kg (6-7 day pregnant) Reproductive: Effects on newborn: Other neonatal measures or effects JPETAB 101,362,1951
intraperitoneal
mouse 		lowest published toxic dose: 800 µg/kg (1 day male) Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) CNREA8 42,122,1982
intraperitoneal
mouse 		lowest published toxic dose: 500 µg/kg (12 day pregnant) Reproductive: Effects on embryo or fetus: Cytological changes (including somatic cell genetic material) TCMUD8 3,281,1983
intraperitoneal
rat 		lowest published toxic dose: 300 µg/kg (11 day pregnant) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) CANCAR 9,955,1956
intraperitoneal
rat 		lowest published toxic dose: 300 µg/kg (12 day pregnant) Reproductive: Specific developmental abnormalities: Musculoskeletal system CANCAR 9,955,1956
intraperitoneal
rat 		lowest published toxic dose: 800 µg/kg (4 day pregnant) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Other developmental abnormalities 		ARZFAN 20,47,1966
intravenous
mouse 		lowest published toxic dose: 800 µg/kg (1 day male) Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) CNREA8 42,122,1982
intravenous
rat 		lowest published toxic dose: 200 µg/kg (10 day pregnant) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Other developmental abnormalities 		JLCMAK 36,833,1950
parenteral
mouse 		lowest published toxic dose: 1 mg/kg (11 day pregnant) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Musculoskeletal system 		TCMUD8 3,281,1983
subcutaneous
rat 		lowest published toxic dose: 1 mg/kg (12 day pregnant) Reproductive: Effects on embryo or fetus: Cytological changes (including somatic cell genetic material) JEEMAF 18,215,1967


TUMORIGENIC DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intraperitoneal
mouse 		lowest published toxic dose: 69 mg/kg/39 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors 		SCIEAS 147,1443,1965
intravenous
mouse 		lowest published toxic dose: 10 mg/kg/42 day- intermittent Tumorigenic: Neoplastic by RTECS criteria

Blood: Leukemia

Blood: Lymphoma including Hodgkin's disease 		CNREA8 25,20,1965
intravenous
rat 		lowest published toxic dose: 5,720 µg/kg/1 year- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Gastrointestinal: Tumors

Blood: Leukemia 		ARZNAD 20,1461,1970
skin
man 		lowest published toxic dose: 153 mg/kg/3 year- continuous Tumorigenic: Carcinogenic by RTECS criteria

Skin and Appendages: Tumors 		ADVEA4 58,421,1978
skin
mouse 		lowest published toxic dose: 60 mg/kg/14 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Skin and Appendages: Tumors 		BJCAAI 9,177,1955
skin
mouse 		toxic dose : 276 mg/kg/23 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Skin and Appendages: Other: Hair

Skin and Appendages: Tumors 		EXPEAM 36,1211,1980
skin
woman 		lowest published toxic dose: 5,840 mg/kg/8 year- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Skin and Appendages: Tumors 		ADVEA4 58,421,1978
skin
woman 		toxic dose : 256 mg/kg/8.5 year- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Skin and Appendages: Tumors 		ADVED7 111,127,1984


ACUTE TOXICITY DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
intracerebral
rat 		lethal dose (50 percent kill): 125 µg/kg N/R JPPMAB 18,760,1966
inhalation
cat 		lowest published lethal concentration: 290 mg/m3/10 minute Behavioral: Irritability

Lung, Thorax, or Respiration: Other changes 		NDRC** NDCrc-132,APR1942
intraperitoneal
mouse 		lethal dose (50 percent kill): 2,400 µg/kg N/R ARZNAD 22,1921,1972
intraperitoneal
rat 		lethal dose (50 percent kill): 860 µg/kg N/R PHMGBN 1,154,1968
intravenous
chicken 		lethal dose (50 percent kill): 10 mg/kg N/R NTIS** PB158-507
intravenous
dog 		lethal dose (65 percent kill): 1 mg/kg N/R NTIS** PB158-507
intravenous
mouse 		lethal dose (50 percent kill): 2 mg/kg N/R NTIS** PB158-507
intravenous
pigeon 		lowest published lethal dose: 15 mg/kg N/R NTIS** PB158-507
intravenous
rat 		lethal dose (50 percent kill): 1,100 µg/kg N/R NTIS** PB158-507
intravenous
rabbit 		lethal dose (50 percent kill): 1,600 µg/kg N/R NTIS** PB158-507
oral
domestic animal 		lowest published lethal dose: 100 mg/kg N/R NTIS** PB158-507
oral
guinea pig 		lethal dose (50 percent kill): 12 mg/kg N/R NTIS** PB158-507
oral
mouse 		lethal dose (50 percent kill): 10 mg/kg N/R NTIS** PB158-507
oral
rat 		lethal dose (50 percent kill): 10 mg/kg N/R NTIS** PB158-507
oral
rabbit 		lethal dose (50 percent kill): 5 mg/kg N/R NTIS** PB158-507
subcutaneous
guinea pig 		lethal dose (50 percent kill): 2 mg/kg Lung, Thorax, or Respiration: Acute pulmonary edema NTIS** PB158-507
subcutaneous
mouse 		lethal dose (50 percent kill): 2,600 µg/kg N/R NTIS** PB158-507
subcutaneous
rat 		lethal dose (50 percent kill): 1,200 µg/kg N/R PSEBAA 83,376,1953
subcutaneous
rabbit 		lethal dose (50 percent kill): 3 mg/kg N/R NTIS** PB158-507
skin
domestic animal 		lethal dose (50 percent kill): 20 mg/kg N/R NTIS** PB158-507
skin
guinea pig 		lowest published toxic dose: 6 mg/kg Skin: After systemic exposure: Dermatitis, irritative

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Peptidases 		ARTODN 76,119,2002
skin
monkey 		lowest published lethal dose: 50 mg/kg N/R NTIS** PB158-507
skin
mouse 		lethal dose (50 percent kill): 29 mg/kg N/R JPETAB 91,224,1947
skin
rat 		lethal dose (50 percent kill): 12 mg/kg N/R FAATDF 5,S160,1985
skin
rabbit 		lethal dose (50 percent kill): 12 mg/kg N/R NTIS** PB158-507
unreported route
rat 		lethal dose (50 percent kill): 1,700 µg/kg N/R PHBUA9 1,297,1953


OTHER MULTIPLE DOSE DATA AND REFERENCES:

ROUTE/
ORGANISM 		DOSE
EFFECT

 REFERENCE
N/R
 N/R N/R N/R


REVIEWS:

ORGANIZATION STANDARD
REFERENCE
International Agency for Research on Cancer (IARC) Cancer Review Animal Sufficient Evidence IMSUDL 7,269,1987
International Agency for Research on Cancer (IARC) Cancer Review Human Limited Evidence IMSUDL 7,269,1987
International Agency for Research on Cancer (IARC) Cancer Review Group 2A IMSUDL 7,269,1987
TOXICOLOGY REVIEW
MUREAV 544,179,2003
TOXICOLOGY REVIEW
MIMDAL 57,19,1974
TOXICOLOGY REVIEW
JAMAAP 172,1765,1960
TOXICOLOGY REVIEW
32XPAD -,49,1975
TOXICOLOGY REVIEW
CLPTAT 5,480,1964
TOXICOLOGY REVIEW
ADVPA3 4,263,1966
TOXICOLOGY REVIEW
ARVPAX 5,447,1965
TOXICOLOGY REVIEW
BMJOAE 2,1055,1961
TOXICOLOGY REVIEW
MUTAEX 17,149,2002
TOXICOLOGY REVIEW
MUREAV 613,17,2006
TOXICOLOGY REVIEW
DIMON* 39,678,1993
TOXICOLOGY REVIEW
ENTOX* -,319,2005
TOXICOLOGY REVIEW
FCTOD7 44,1699,2006
TOXICOLOGY REVIEW
MUREAV 627,10,2007
TOXICOLOGY REVIEW
ENTOX* -,241,2005
TOXICOLOGY REVIEW
MUREAV 584,1,2005


STANDARDS AND REGULATIONS:

ORGANIZATION STANDARD
REFERENCE
N/R N/R N/R


NIOSH DOCUMENTATION AND SURVEILLANCE:

ORGANIZATION STANDARD or SURVEY
REFERENCE
National Occupational Exposure Survey 1983 National Occupational Exposure Survey 1983: Hazard Code: X4741;
Number of Industries 1;
Total Number of Facilities 205;
Number of Occupations 6;
Total Number of Employees Exposed 4,565;
Total Number of Female Employees Exposed 2,036


STATUS IN FEDERAL AGENCIES:

ORGANIZATION
REFERENCE
EPA GENETOX PROGRAM 1988, Positive: Carcinogenicity-mouse/rat
EPA GENETOX PROGRAM 1988, Positive: In vivo cytogenetics-human lymphocyte
EPA GENETOX PROGRAM 1988, Positive: D melanogaster-reciprocal translocation
EPA GENETOX PROGRAM 1988, Positive: Host-mediated assay
EPA GENETOX PROGRAM 1988, Positive: In vitro mammalian nonhuman micronucleus
EPA GENETOX PROGRAM 1988, Positive: Mammalian micronucleus; N crassa-reversion
EPA GENETOX PROGRAM 1988, Positive: Histidine reversion-Ames test; Sperm morphology-mouse
EPA GENETOX PROGRAM 1988, Positive: D melanogaster Sex-linked lethal; TRP reversion
EPA GENETOX PROGRAM 1988, Positive: S cerevisiae-forward mutation; S cerevisiae-reversion
EPA GENETOX PROGRAM 1988, Positive/dose response: In vitro SCE-nonhuman
EPA GENETOX PROGRAM 1988, Positive/dose response: In vitro UDS-human fibroblast
EPA GENETOX PROGRAM 1988, Inconclusive: Rodent heritable translocation
EPA TSCA Section 8(b) CHEMICAL INVENTORY
Used as a vesicant in chemical warfare, and as a chemical intermediate
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001


REFERENCES:

CODEN
REFERENCE
32XPAD "Teratology," Berry, C.L., and D.E. Poswillo, eds., New York, Springer, 1975
ABBIA4 Archives of Biochemistry and Biophysics. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.31- 1951-
ADVEA4 Acta Dermato-Venereologica. (Almqvist & Wiksell, POB 45150, S-10430 Stockholm, Sweden) V.1- 1920-
ADVED7 Annales de Dermatologie et de Venereologie. (Masson Editeur, 120 Blvd. Saint-Germain, F-75280 Paris Cedex 06, France) V.104- 1977-
ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ.
AESAAI Annals of the Entomological Society of America. (Entomological Soc. of America, 4603 Calvert Rd., College Park, MD 20740) V.1- 1908-
AJOPAA American Journal of Ophthalmology. (Ophthalmic Pub. Co., 435 N. Michigan Ave., Suite 1415, Chicago, IL 60611) Series 3: V.1- 1918-
APMBAY Applied Microbiology. (Washington, DC) V.1-30, 1953-75. For publisher information, see AEMIDF.
APTOA6 Acta Pharmacologica et Toxicologica. (Copenhagen, Denmark) V.1-59, 1945-86. For publisher information, see PHTOEH
ARTODN Archives of Toxicology. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.32- 1974-
ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI.
ARZFAN Aerztliche Forschung. (Munich, Fed. Rep. Ger.) V.1-26, 1947-72. Discontinued.
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951-
BBACAQ Biochimica et Biophysica Acta. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1947-
BCPCA6 Biochemical Pharmacology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 1958-
BEXBAN Bulletin of Experimental Biology and Medicine (English Translation). Translation of BEBMAE. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013) V.41- 1956-
BIJOAK Biochemical Journal. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1906-
BIZNAT Biologisches Zentralblatt. (VEB Georg Thieme, Postfach 946, Leipzig DDR-7010, Ger. Dem. Rep.) V.1- 1881-
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947-
BJDEAZ British Journal of Dermatology. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.63- 1951-
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857-
CALEDQ Cancer Letters (Shannon, Ireland). (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1975-
CANCAR Cancer (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1948-
CBINA8 Chemico-Biological Interactions. (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1969-
CLPTAT Clinical Pharmacology and Therapeutics. (American Society for Clinical Pharmacology and Therapeutics, St. Louis Mo Mosby-Year Book) V.1- 1960-
CMMUAO Chemical Mutagens. Principles and Methods for Their Detection. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013) V.1- 1971-
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941-
COREAF Comptes Rendus Hebdomadaires des Seances, Academie des Sciences. (Paris, France) V.1-261, 1835-1965. For publisher information, see CRASEV.
CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980-
CTKIAR Cell and Tissue Kinetics. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.1- 1968-
CTRRDO Cancer Treatment Reports. (Washington, DC) V.60-71, 1976-87. For publisher information, see JNCIEQ.
DIMON* Disease-a Month (Chicago : Year Book Publishers) V. 24- 1978-
EJCAEL European Journal of Cancer. (Pergamon Press, c/o Elsevier Science, 660 White Plains Rd., Tarrytown, NY 10591) V.26-28(2/3), 1990-92. For publisher information, see EJCTEA
EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987-
ENTOX* Encyclopedia of Toxicology: Reference Book, Elsevier, 2005
EXPEAM Experientia. (Birkhaeuser Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1945-
FAATDF Fundamental and Applied Toxicology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-40, 1981-97. For publisher information, see TOSCF2
FCTOD7 Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.20- 1982-
FOMIAZ Folia Microbiologica (Prague). (Academia, Vodickova 40, 112 29 Prague 1, Czechoslavakia) V.4- 1959-
GENTAE Genetics. (Genetics Business Office, POB 64025, Baltimore, MD 21264) V.1- 1916-
IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979-
INOPAO Investigative Ophthalmology. (St. Louis, MO) V.1-15, 1962-76. For publisher information, see IOVSDA.
JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1883-
JAPTO* Journal of Applied Toxicology (John Wiley & Sons, Ltd., Oldlands Way Bognor Regis West Sussex, PO22 9SA England) V.1- 1981-
JCLLAX Journal of Cellular Physiology. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.67- 1966-
JEEMAF Journal of Embryology and Experimental Morphology. (Essex, UK) V.1-98, 1953-86. For Publisher information, see DEVPED
JGMIAN Journal of General Microbiology. (Soc. for General Microbiology, Journal Sales, 62 London Rd., Reading, RG1 5AS, UK) V.1- 1947-
JIDEAE Journal of Investigative Dermatology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1938-
JLCMAK Journal of Laboratory and Clinical Medicine. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63141) V.1- 1915-
JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8.
JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10-
JPPMAB Journal of Pharmacy and Pharmacology. (Pharmaceutical Soc. of Great Britain, 1 Lambeth High St., London SEI 7JN, UK) V.1- 1949-
JTEHD6 Journal of Toxicology and Environmental Health. (Hemisphere Pub., 1025 Vermont Ave., NW, Washington, DC 20005) V.1- 1975/76-
LBANAX Laboratory Animals. (Laboratory Animals Ltd., 1 Thrifts Mead, Theydon Bois, Essex CM16 7NF, UK) V.1- 1967-
MGGEAE Molecular and General Genetics. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.99- 1967-
MIMDAL Minnesota Medicine. (Minnesota Medical Assoc., 2221 University Ave., SE, Suite 400, Minneapolis, MN 55414) V.1- 1918-
MOPMA3 Molecular Pharmacology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1965-
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-
MUTAEX Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1986-
NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869-
NDRC** National Defense Research Committee, Office of Scientific Research and Development, Progress Report.
NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information.
OFAJAE Okajimas Folia Anatomica Japonica. (Keio Univ., School of Medicine, Dept. of Anatomy, 35 Shinano-machi, Shinjuku-ku, Tokyo 160, Japan) V.14- 1936-
PAACA3 Proceedings of the American Association for Cancer Research. (Waverly Press, 428 E. Preston St., Baltimore, MD 21202) V.1- 1954-
PACHAS Pure and Applied Chemistry. (Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW, UK) V.1- 1960-
PHARAT Pharmazie. (VEB Verlag Volk und Gesundheit, Neue Gruenstr. 18, Berlin DDR-1020, Ger. Dem. Rep.) V.1- 1946-
PHBUA9 Pharmaceutical Bulletin. (Tokyo, Japan) V.1-5, 1953-57. For publisher information, see CPBTAL.
PHMGBN Pharmacology: International Journal of Experimental and Clinical Pharmacology. (S. Karger AG, Postfach CH-4009 Basel, Switzerland) V.1- 1968-
PNASA6 Proceedings of the National Academy of Sciences of the United States of America. (National Academy of Sciences, Printing & Pub. Office, 2101 Constitution Ave., Washington, DC 20418) V.1- 1915-
PREBA3 Proceedings of the Royal Society of Edinburgh, Section B. (Edinburgh, Scotland, UK) V.61-74, 1943-74.
PSEBAA Proceedings of the Society for Experimental Biology and Medicine. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1903/04-
RCOCB8 Research Communications in Chemical Pathology and Pharmacology. (PJD Pub. Ltd., P.O. Box 966, Westbury, NY 11590) V.1- 1970-
SCIEAS Science. (American Assoc. for the Advancement of Science, 1333 H St., NW, Washington, DC 20005) V.1- 1895-
TAKHAA Takeda Kenkyusho Ho. Journal of the Takeda Research Laboratories. (Takeda Yakuhin Kogyo K.K., 2-17-85 Jusohon-machi, Yodogawa-ku, Osaka 532, Japan) V.29- 1970-
TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980-
TOXID9 Toxicologist. (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-
TXCYAC Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973-
ZKKOBW Zeitschrift fuer Krebsforschung und Klinische Onkologie. (Berlin, Fed. Rep. Ger.) V.76-92, 1971-78. For publisher information, see JCROD7.

Used as a vesicant in chemical warfare, and as a chemical intermediate

RTECS Compound Description:
   Tumorigen
   Drug
   Mutagen
   Reproductive Effector
   Human Data
   Primary Irritant

 Click Here for Additional Information about RTECS